Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors.
Adult
Blood Vessels
/ metabolism
Breast Neoplasms
/ diagnosis
Correlation of Data
Cross-Sectional Studies
Epithelial Cells
/ metabolism
Female
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Immunohistochemistry
Ki-67 Antigen
/ metabolism
Lymphatic Metastasis
Melatonin
/ pharmacology
Middle Aged
Receptor, ErbB-2
/ metabolism
Receptor, Melatonin, MT1
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
Triple Negative Breast Neoplasms
/ metabolism
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
11
7
2019
medline:
27
7
2021
entrez:
11
7
2019
Statut:
ppublish
Résumé
Breast carcinoma is a multifaceted-etiology malignancy. The presence of estrogen (ER), progesterone (PR), and HER2 (human epidermal growth factor receptor 2) receptors in breast carcinoma tissue has therapeutic implications. Recent studies indicate that pineal hormone melatonin by its receptor melatonin 1 (MT1) also influences the development and growth of breast cancer cells. The aim of this cross-sectional study was to elucidate the expression pattern of MT1 receptor in relation to estrogen, progesterone, and HER2 receptors in breast carcinoma. Two groups (receptor positive and triple negative) of breast carcinoma were taken. For comparison, normal mammary tissue was used as control. Immunohistochemistry was carried out using anti-melatonin receptor 1A antibody. Membranous/cytoplasmic expression was seen more than the nuclear expression in the cancerous tissue. Positive correlation of the MT1 expression was seen with ER, PR, and HER 2 receptor. Higher MT1 receptor expression was seen in the receptor-positive cases in comparison with triple-negative cases, which might signify melatonin deficiency in the former, leading to reactive increase in cell receptors. No correlation of MT1 expression with Ki67 index or lymph node status in both receptor-positive and triple-negative cases was found. Normal mammary tissue mainly showed cytoplasmic MT1 immunoreactivity of epithelial cells (ducts and acini), myoepithelial cells, and lining epithelium of blood vessels. Receptor-positive cases would, therefore, benefit from the use of melatonin as supporting therapy. This indicates that melatonin receptor status can be used as an independent pathologic indicator to evaluate breast carcinoma tissue, and melatonin receptor status may help to determine treatment protocols.
Identifiants
pubmed: 31290783
doi: 10.1097/PAI.0000000000000788
pii: 00129039-202008000-00006
doi:
Substances chimiques
Ki-67 Antigen
0
MKI67 protein, human
0
Receptor, Melatonin, MT1
0
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
518-523Références
Movahedi M, Haghighat S, Khayamzadeh M, et al. Survival rate of breast cancer based on geographical variation in Iran, a national study. Iran Red Crescent Med J. 2012;14:798–804.
Turkoz FP, Solak M, Petekkaya I, et al. Association between common risk factors and molecular subtypes in breast cancer patients. Breast. 2013;22:344–350.
Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol. 2008;66:65–74.
Andersa CK, Johnsonb R, Littonc J, et al. Breast cancer before age 40 years. Semin Oncol. 2009;36:237–249.
Knower KC, To SQ, Takagi K, et al. Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat. 2012;132:765–771.
Ramezanpour H, Setayeshi S, Akbari M. A novel scheme for optimal control of a nonlinear delay differential equations model to determine effective and optimal administrating chemotherapy agents in breast cancer. Iran J Cancer Prev. 2012;4:154–162.
Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 1995;71:854–856.
Sa´nchez-Barcelo EJ, Cos S, Mediavilla D, et al. Melatonin–estrogen interactions in breast cancer. J Pineal Res. 2005;38:217–222.
Bonnefont-Rousselot D, Collin F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology. 2010;278:55–67.
Fernández-Mar MI, Mateos R, García-Parrilla MC, et al. Bioactive compounds in wine: resveratrol, hydroxytyrosol and melatonin: a review. Food Chem. 2012;130:797–813.
Reiter RJ, Tan D-X, Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res. 2010;181:127–151.
Miller SC, Pandi-Perumal SR, Esquifino AI, et al. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol. 2006;87:81–87.
Montilla P, Cruz A, Padillo FJ, et al. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res. 2001;31:138–144.
Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 1978;312:814–816.
Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res. 1988;48:6121–6126.
Cos S, Blask DE, Lemus-Wilson A, et al. Effects of melatonin on the cell cycle kinetics and “estrogen-rescue” of MCF-7 human breast cancer cells in culture. J Pineal Res. 1991;10:36–42.
Slaugenhaupt SA, Roca AL, Liebert CB, et al. Mapping of the gene for the Mel1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics. 1995;27:355–357.
Gupta T, Sahni D, Gupta R, et al. Expanding the horizons of melatonin use: an immunohistochemical neuroanatomic distribution of MT1 and MT2 receptors in human brain and retina. J Anat Soc India. 2017;66:58–66.
Reppert SM, Godson C, Mahle CD, et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1B melatonin receptor. Proc Natl Acad Sci USA. 1995;92:8734–8738.
Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994;13:1177–1185.
Dubocovich ML, Masana MI, Iacob S, et al. Melatonin receptor antagonists that differentiate between the mel1a and mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:365–375.
Grant SG, Melan MA, Latimer JJ, et al. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med. 2009;11:e5.
Bartsch C, Bartsch H, Karenovics A, et al. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. J Pineal Res. 1997;23:53–58.
Rondanelli M, Faliva MA, Perna S, et al. Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin Exp Res. 2013;25:499–510.
Dauchy RT, Xiang S, Mao L, et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res. 2014;74:4099–4110.
Jung B, Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res. 2006;66:9789–9793.
Arif IS, Hooper CL, Greco F, et al. Increasing doxorubicin activity against breast cancer cells using PPARc-ligands and by exploiting circadian rhythms. Br J Pharmacol. 2013;169:1178–1188.
Ma C, Li LX, Zhang Y, et al. Protective and sensitive effects of melatonin combined with adriamycin on ER+ (estrogen receptor) breast cancer. Eur J Gynaecol Oncol. 2015;36:197–202.
Dhillon DC, Easley SE, Asch BB, et al. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol. 2002;118:451–458.
Lai L, Yuan L, Cheng Q, et al. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat. 2009;118:293–305.
Jablonska K, Pula B, Zemla A, et al. Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. J Pineal Res. 2013;54:334–345.
Hsu SM, Raine L, Fanger H. Use of biotin-avidin peroxidase complex (ABC) in immunoperoxidase technique: comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577–580.
Remmele W, Stegner He. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–140.
Goyal R, Gupta T, Gupta R, et al. Histological and immunohistochemical study of estrogen and progesterone receptors in normal human breast tissue in adult age groups vulnerable to malignancy. Clinical Anatomy. 2016;29:729–737.
Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, et al. Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs. 2012;21:819–831.
Griffin F, Marignol L. Therapeutic potential of melatonin for breast cancer radiation therapy patients. Int J Radiat Biol. 2018;94:472–477.
Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8:39896–39921.